EFFECT OF IBANDRONATE ON RISKS FOR VERTEBRAL AND NONVERTEBRAL FRACTURES IN POSTMENOPAUSALOSTEOPOROSIS (A REVIEW OF CLINICAL TRIALS)
The paper presents data of a large number of clinical trials meeting the principles of evidence-based medicines, which have dealt with the evaluation of the efficacy of ibandronate in postmenopausal osteoporosis (OP). The administration of its registered formulations (150 mg weekly oral and 3 mg qua...
Main Author: | Evgeni Germanovich Zotkin |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2010-06-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/286 |
Similar Items
-
EFFECT OF IBANDRONATE ON RISKS FOR VERTEBRAL AND NONVERTEBRAL FRACTURES IN POSTMENOPAUSALOSTEOPOROSIS (A REVIEW OF CLINICAL TRIALS)
by: Evgeni Germanovich Zotkin
Published: (2010-06-01) -
Open, Prospective, Multi-Center, Two-Part Study of Patient Preference with Monthly Ibandronate Therapy in Women with Postmenopausal Osteoporosis Switched From Daily or Weekly Alendronate or Risendronate-BONCURE: Results of Turkish Sub-Study
by: Nurten Eskiyurt, et al.
Published: (2012-04-01) -
First Indian prospective randomized comparative study evaluating adherence and compliance of postmenopausal osteoporotic patients for daily alendronate, weekly risedronate and monthly ibandronate regimens of bisphosphonates
by: Vishal R Tandon, et al.
Published: (2014-01-01) -
Osteoporosis in women in menopause/postmenopause: what to do?
by: E. V. Kulchavenya, et al.
Published: (2021-01-01) -
Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment
by: Richard Derman, et al.
Published: (2009-09-01)